Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6002 vs Chemotherapy in Recurrent or Metastatic Cervical Cancer
NCT07230626Phase 3Not yet recruiting
- Sponsor
- CSPC Megalith Biopharmaceutical Co., Ltd.
- Start
- Nov 2025
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
01
Overview
A Phase 3 trial of CRB-701 in Cervical Cancer (CC), sponsored by CSPC Megalith Biopharmaceutical Co., Ltd.. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
CRB-701
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT07230626.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230626.